Clinical Trials Logo

Clinical Trial Summary

This is a randomized double blind controlled study to determine if celebrex (celecoxib), a selective COX-2 inhibitor, can decrease the rate of recurrence in adult and pediatric patients with recurrent respiratory papillomatosis. All patients will be evaluated for disease severity at enrollment and at 3 month intervals for 30 months. After randomization, patients in the early treatment arm will begin celecoxib 6 months after enrollment. The delayed treatment arm will begin celecoxib 18 months after enrollment. All patients will receive celecoxib for 1 year. During the time that patients do no receive celecoxib, they will receive a placebo capsule with the same appearance. Follow-up visits will occur at three month intervals for the duration of the study.


Clinical Trial Description

This is a randomized double blind placebo-controlled study,with plans to include 5 additional U.S. centers in the near future. The primary goal of this study is to determine whether celecoxib has efficacy in elimination or reduction of recurrent disease in patients with RRP. Our secondary goals are to determine whether continued celecoxib is required to maintain response, to correlate response with select patient demographics and persistence of latent HPV DNA, and to determine whether celecoxib is acting through inhibition of COX-2, in order to begin to determine mechanism of effects in vivo on RRP. The study design encompasses a 30-month period, which can be divided into three segments:

Segment A: This is a 6 month run-in period in which all patients are assessed by direct laryngoscopy/bronchoscopy for disease severity, to permit growth rate stabilization and confirm accuracy of training of participating physicians. Patients will be treated by conventional surgery at three months and six months after enrollment.

Segment B: Patients begin 12 months of 400mg(adults), 100 mg (pediatric weight between 12 and 25 kg)or 200 mg (pediatric weight > 25kg) celecoxib daily or placebo treatment in addition to surgical removal of all papillomas at each 3 month interval. This segment directly tests the hypothesis that celecoxib is an efficacious treatment for moderate to severe RRP and forms the basis for the primary statistical analyses.

Segment C: The primary purpose of this segment is to determine whether gains made during celecoxib therapy are maintained after it is discontinued, or whether celecoxib will need to be taken indefinitely. This will be determined by a 12 month period on placebo after cessation of celecoxib for the early treatment group. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00571701
Study type Interventional
Source Northwell Health
Contact
Status Completed
Phase Phase 2
Start date February 2008
Completion date January 2015

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02854761 - Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP) Phase 1
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4
Completed NCT01020747 - Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP) Phase 1
Completed NCT00038714 - A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis Phase 2
Completed NCT00205374 - Use of Cidofovir for Recurrent Respiratory Papillomatosis Phase 4
Active, not recruiting NCT04724980 - Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis Phase 1/Phase 2
Not yet recruiting NCT04645602 - Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Withdrawn NCT01058317 - Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Phase 2/Phase 3
Withdrawn NCT00829608 - Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis Phase 0
Completed NCT00550914 - Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP N/A
Not yet recruiting NCT01995721 - 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Phase 3
Completed NCT02217358 - Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions N/A
Recruiting NCT02555800 - Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis Phase 2
Completed NCT03707587 - M7824 in People With Recurrent Respiratory Papillomatosis Phase 2
Completed NCT02859454 - Avelumab for People With Recurrent Respiratory Papillomatosis Phase 2
Active, not recruiting NCT02632344 - Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients Phase 2
Completed NCT02592902 - Recurrent Respiratory Papillomatosis and Extraesophageal Reflux N/A
Recruiting NCT06412172 - The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
Recruiting NCT03465280 - Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)